GENEVA/LONDON: Some 172 countries are engaging with the WHO-led COVAX plan designed to ensure equitable access to COVID-19 vaccines, the World Health Organization said on Monday, but more funding is urgently needed and countries should now make binding commitments.
“Initially, when there will be limited supply (of COVID-19 vaccines), it’s important to provide the vaccine to those at highest risk around the globe,” the WHO’s director general Tedros Adhanom Ghebreyesus told a media briefing.
The COVAX Facility forms a key part of the COVAX pillar (COVAX) of the Access to COVID-19 Tools (ACT) Accelerator, a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines.
COVAX is co-led by vaccine alliance Gavi, the Coalition for Epidemic Preparedness Innovations (CEPI) and WHO, working in partnership with developed and developing country vaccine manufacturers.
COVAX aims to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world.
It will achieve this by sharing the risks associated with vaccine development, investing in manufacturing upfront so vaccines can be deployed at scale as soon as they are proven successful, and pooling procurement and purchasing power to achieve sufficient volumes to end the acute phase of the pandemic by 2021.
